We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA's CRITICAL PATH SHOULD FOCUS ON BIOMARKERS AND STUDIES, PANEL SAYS
FDA's CRITICAL PATH SHOULD FOCUS ON BIOMARKERS AND STUDIES, PANEL SAYS
November 12, 2004
The development of new biomarkers and standardizing clinical trial data-gathering should be initial focuses of the FDA’s Critical Path Initiative, which aims to expedite the drug development process and bring more products to market faster, according to the FDA’s Science Board.